-By ArdorComm News Network
February 25, 2025
Hyderabad-based pharmaceutical company Granules India has acquired Switzerland-based CDMO firm Senn Chemicals AG for CHF 20 million (₹192 crore), marking its foray into the Contract Development and Manufacturing Organization (CDMO) space.
Senn Chemicals specializes in peptide synthesis and peptide-based applications, catering to global clients with contract research, development, and manufacturing services. The acquisition is expected to be completed in the first half of 2025, Granules India stated.
“By entering the rapidly growing peptide therapeutics segment and acquiring CDMO capabilities, we are expanding into next-generation therapeutics that align with our commitment to innovation and affordability,” said Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India.
With Senn’s expertise in peptide synthesis and Granules’ large-scale, cost-efficient manufacturing capabilities, the company aims to deliver high-quality peptide-based solutions globally.
Rico Wiedenbruch, Chairman of Senn Chemicals AG, emphasized the strategic fit between the two companies:
“With Granules’ scale, operational efficiency, and global reach in the pharmaceutical industry, we see tremendous potential to accelerate our growth and expand our capabilities in the rapidly growing peptide therapeutics segment.”
This acquisition strengthens Granules India’s position in the global pharmaceutical landscape, expanding its footprint in next-generation therapeutics and peptide-based drug development.
Source: Business Standard